in RNA Therapeutics
AlphaNa is an innovation-driven bioscience company focused on addressing critical unmet medical needs by translating original RNA research into high-quality therapeutics with clinical value. Built upon our proprietary TALENT® platform, we have established a R&D portfolio across three core areas including in vivo cell engineering, next-generation nucleic acid therapeutics, and innovative vaccines, with multiple pipelines advancing into pivotal clinical stages. AlphaNa has led and participated in 7 national-level key research programs as well as multiple provincial and ministerial initiatives, and is continuously strengthening an intellectual property portfolio comprising nearly 100 patents and patent applications. We are building an integrated research and industrialization ecosystem spanning drug discovery, clinical translation, and bio-manufacturing.
AFN50 is an mRNA-based in vivo CAR-T program designed to directly program and activate T cells in vivo for the selective elimination of pathogenic immune cells in autoimmune diseases. The program is currently being evaluated in investigator-initiated trials (IIT).
Contact us
AFN52 is an in vivo CAR-T program targeting solid tumors, leveraging AlphaNa’s proprietary immune cell programming and delivery platform to generate functional CAR-T cells directly in vivo without ex vivo manipulation. The program is currently in IIT studies.
Contact us
AFN56 is a first-in-class in vivo Tol-APC program that directly generates tolerogenic antigen-presenting cells in vivo to induce immune tolerance and suppress aberrant immune responses in autoimmune diseases. The program is currently in IIT studies.
Contact us
AFN03 is a therapeutic mRNA-based nucleic acid program for HPV16/18-related diseases. The program is in Phase II for HPV16/18-associated precancerous lesions and Phase I clinical trials for cervical cancer, head and neck cancer, and other solid tumors.
Contact us
AFN03 is a therapeutic mRNA-based nucleic acid program for HPV16/18-related diseases. The program is in Phase II for HPV16/18-associated precancerous lesions and Phase I clinical trials for cervical cancer, head and neck cancer, and other solid tumors.
Contact us
AFN02 is a prophylactic mRNA vaccine targeting respiratory syncytial virus (RSV) and is currently in Phase II clinical development. It represents one of the most advanced and potentially first-in-class mRNA RSV vaccine programs in China.
Contact us
AFN12 is an mRNA vaccine candidate for the prevention of Herpes Zoster and is currently in Phase I clinical development, further expanding the company’s portfolio in prophylactic vaccines.
Contact usin vivo CAR-T
AFN50
AFN52
Autoimmune Diseases
Cancer
in vivo Tol-APC
AFN56
Autoimmune Diseases
Next-Generation Nucleic Acid Therapeutics
AFN03
AFN03
HPV16/18-associated cervical HSIL
Cervical cancer/HNSCC
Novel Vaccines
AFN02
AFN12
Respiratrory Syncytial Virus (RSV)
Herpes Zoster
Please use the provided form to submit questions, requests for information, or business development inquiries
